Skip to main content
Premium Trial:

Request an Annual Quote

Berlin Molecular Medicine Center Purchases Pyrosequencing Genotyping System

NEW YORK, Dec. 12 — Berlin’s Max Delbruck Center for Molecular Medicine bought a high-throughput genotyping system from Pyrosequencing, the company announced today.

The Berlin institution’s Gene Mapping Center and Department of Molecular Genetics will use Pyrosequencing’s Preferred Technology Program for SNP analysis in research into the genetics of complex diseases. Researchers will also collaborate with Pyrosequencing to continue to develop and expand the capacity of the system.

Pyrosequencing’s automated PTP system, with 384-well microplates, can score up to 100,000 SNPs per day, according to the company. The product, which was introduced earlier this year, sells for $350,000 but can go for more than $1 million with additional robotics, a spokeswoman said.

“We explored a number of SNP technologies but chose PTP because we have had impressive results with Pyrosequencing’s PSQ 96 System. Our need to analyze more samples is increasing, and PTP offers a more cost-effective solution based on the same technology,” said GMC head Peter Nurnberg in a statement. The Gene Mapping Center is a specialized lab for high-throughput genotyping for monogenic and complex diseases. Projects include studies for genes involved in cancer, high blood pressure, lipid metabolism disorders and brain tumors. Next year, the center plans to double its current annual capacity of approximately 2 million high-quality STR genotypes.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.